These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18034634)

  • 1. What can be learnt from the Japanese regulatory approach to tissue engineered products?
    Brévignon-Dodin L; Livesey F
    Regen Med; 2007 Nov; 2(6):967-71. PubMed ID: 18034634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
    Brévignon-Dodin L
    Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Industrialization of regenerative medicine in Japan].
    Sugawara K; Hata K
    Clin Calcium; 2008 Dec; 18(12):1751-6. PubMed ID: 19043189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical assessment of the directive on tissue engineering of the European union.
    Trommelmans L; Selling J; Dierickx K
    Tissue Eng; 2007 Apr; 13(4):667-72. PubMed ID: 17253926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Same but Different: Regulation of Tissue Engineering and Regenerative Medicine in the Context of Regional and International Standards and Expectations.
    Williams DF
    Tissue Eng Part A; 2015 Dec; 21(23-24):2781-2. PubMed ID: 26486499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
    Jokura Y; Yano K; Yamato M
    J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Supervision, administration and standard research related to tissue engineered medical products].
    Xi TF; Chen L; Zhao P
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional approval: Japan lowers the bar for regenerative medicine products.
    Sipp D
    Cell Stem Cell; 2015 Apr; 16(4):353-6. PubMed ID: 25842975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
    Smith DS
    Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
    [No Abstract]   [Full Text] [Related]  

  • 10. Regenerative medicine 2.0.
    Mason C
    Regen Med; 2007 Jan; 2(1):11-8. PubMed ID: 17465770
    [No Abstract]   [Full Text] [Related]  

  • 11. The implications of "advanced therapies" regulation.
    Sethe SC
    Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the clinical application of regenerative medicine products in Japan.
    Tsubouchi M; Matsui S; Banno Y; Kurokawa K; Kawakami K
    Health Policy; 2008 Oct; 88(1):62-72. PubMed ID: 18395290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STER science and cardiothoracic surgery: an Asian perspective.
    Chiu RC
    Asian Cardiovasc Thorac Ann; 2008 Oct; 16(5):351-2. PubMed ID: 18812339
    [No Abstract]   [Full Text] [Related]  

  • 16. Future of regenerative medicine: challenges and hurdles.
    Shastri VP
    Artif Organs; 2006 Oct; 30(10):828-34. PubMed ID: 17026584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of tissue-engineered products in the European Union: where are we heading?
    Brévignon-Dodin L; Livesey F
    Regen Med; 2006 Sep; 1(5):709-14. PubMed ID: 17465739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Legal regulation in the field of tissue engineering].
    Farkas B; Bárdos T; Bellyei A; Illés T
    Orv Hetil; 2008 Jun; 149(22):1023-8. PubMed ID: 18508736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA regulatory pathways for knee cartilage repair products.
    Levine DW; Mondano L; Halpin M
    Sports Med Arthrosc Rev; 2008 Dec; 16(4):202-7. PubMed ID: 19011551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.